Bruno Golding

NAFLD and NASH Biomarker Qualification in the LITMUS consortium - Lessons learned.

M. Karsdal, D. Schuppan, J. Dufour, 2022, Journal of Hepatology.

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer

H. Klocker, W. Horninger, T. Steuber, 2020, BJUI Compass.

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies

T. Steuber, R. Schiess, P. Tennstedt, 2018, BJU international.

Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer

R. Schiess, A. Macagno, M. Rhiel, 2020, PloS one.

A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: Findings of a recent study

T. Steuber, R. Schiess, P. Tennstedt, 2017 .